**Summary**
Shield Therapeutics plc, a commercial-stage pharmaceutical company specializing in iron deficiency treatments, has been awarded Gold at the 2025 Titan Brand Awards for the successful rebranding of its product, ACCRUFeR®. The award recognizes the companys efforts in transforming ACCRUFeR® into a highly differentiated, patient-focused brand, which has become the #1 branded prescription oral iron in the U.S. ID/IDA market. This achievement highlights Shields commitment to addressing the significant unmet needs of patients and healthcare professionals in managing iron deficiency and iron deficiency anemia (ID/IDA), a condition affecting approximately 20 million people in the U.S. and representing a $2.3B market opportunity. The rebranding initiative is part of a broader digital marketing strategy aimed at driving growth for ACCRUFeR®. The product, also known as FeRACCRU® (ferric maltol), is a novel, stable, non-salt-based oral therapy with a unique absorption mechanism, supported by strong clinical trial data. Shield has established partnerships for the commercialization of ACCRUFeR®/FeRACCRU® globally, with patent protection extending into the mid-2030s.